Neuroendocrine tumours: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R43

  Development of a PET Imaging Platform to De-Risk AAV Gene Therapy Clinical Trials

  Neocell Technologies Inc· Fair Lawn, United States· US$306,395 awarded in fiscal year 2026· until Sept 2027

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Novel Non-Mutagenic Ribosome Biogenesis Inhibitors for the Treatment of Small Cell Lung Cancer

  Palade Therapeutics Inc.· Austin, United States· US$404,087 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics

  Yale University· New Haven, United States· US$532,637 awarded in fiscal year 2026· until Aug 2031

• NIH NIBIB · U24

  Medical Imaging and Data Resource Center (MIDRC) – Expansion to Theranostics

  University of Chicago· Chicago, United States· US$1,014,676 awarded in fiscal year 2026· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution €321,301· until May 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Differential Detection Electrogravimetric Platform for the Early Diagnosis of Neuroendocrine Tumours (NETSPY)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €268,569· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors. (dIscOverNET)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €4,574,378· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)

  Norges Geotekniske Institutt As· Oslo, Norway· EU contribution €4,773,849· until Dec 2030· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)

  Universite du Luxembourg· Esch-Sur-Alzette, Luxembourg· EU contribution €14,837,694· until Dec 2029· 13 countries

10 of 194 running projects, newest first. Listed amounts together: US$116.1m + €37.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 50
• Metabolomics 20
• Mass Spectrometry 5
• Flow Cytometry 55
• Immunohistochemistry 186
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 202
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Capture and Isolation of Circulating Melanoma Cells Using Photoacoustic Flowmetry.

  Methods Mol Biol, Jan 2027

• Imaging and Analysis of Melanoma-Secreted Extracellular Vesicles in Tumor-Draining Lymph Nodes.

  Methods Mol Biol, Jan 2027

• A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.

  Methods Mol Biol, Jan 2027

• A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.

  Methods Mol Biol, Jan 2027

• Evaluating Melanoma Cell Migration/Invasion in Transwell Assays by Flow Cytometry.

  Methods Mol Biol, Jan 2027

• Anti-tumour activity of canine activated T-cells and cytokine-induced killer cells against canine malignant melanoma in vitro.

  Vet J, Jul 2026

• Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.

  Diagn Cytopathol, Jul 2026

• LNP-Delivered CAR-mRNA Enables in Vivo CAR-Macrophage Production for TYRP1-Targeted Therapy of Choroidal Melanoma.

  Curr Eye Res, Apr 2026

• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

  Eur J Surg Oncol, Jan 2026

• PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

  Nat Commun, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.